J&J's China Pill Approval Puts Pressure on Immunology Franchise

Johnson & Johnson (JNJ) has secured approval in China for its once-daily pill, Icotyde. This marks a significant milestone for the company as it looks to tap into the massive market of patients living with moderate-to-severe plaque psoriasis.

A staggering 8.4 million people in China suffer from this condition, creating a substantial target market for Icotyde. The pill works by blocking the IL-23 receptor through an oral peptide, offering a convenient alternative to injectable treatments like J&J's own Tremfya.

However, the commercial implications of Icotyde's approval are complex. While it may defend J&J's immunology franchise as Stelara loses patent protection, converting existing Tremfya users would largely shift revenue within the company. To achieve real growth, Icotyde needs to attract untreated patients or gain market share from competitors like AbbVie and Bristol Myers Squibb.